Pieris Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Revenue - Narrative (Details)

Revenue - Narrative (Details) $ / shares in Units, $ in Thousands, € in Millions																									1 Months Ended			3 Months Ended		12 Months Ended
	May 19, 2021 USD ($)	May 19, 2021 USD ($)	May 19, 2021 USD ($) lease_agreement	May 19, 2021 USD ($) performance_obligation	May 19, 2021 USD ($) program	Apr. 24, 2021 USD ($)	Apr. 01, 2021 USD ($) $ / shares shares	Mar. 29, 2021 shares	Mar. 24, 2021 USD ($) $ / shares shares	Feb. 08, 2018 USD ($) research_program license performance_obligation program swap_option	May 02, 2017 USD ($)	May 02, 2017 USD ($)	May 02, 2017 USD ($) lease_agreement	May 02, 2017 USD ($) performance_obligation	May 02, 2017 USD ($) research_program	May 02, 2017 USD ($) license	May 02, 2017 USD ($) protein	Jan. 04, 2017 collaboration_product product	Jan. 04, 2017 USD ($) collaboration_product product	Jan. 04, 2017 performance_obligation collaboration_product product	Jan. 04, 2017 collaboration_product product program	Jan. 04, 2017 collaboration_product product license	Jan. 04, 2017 bispecific_therapeutic_program collaboration_product product	Jan. 04, 2017 EUR (€) collaboration_product product	Mar. 31, 2021 USD ($)	Feb. 28, 2021	Feb. 29, 2020 program collaboration_product	Mar. 31, 2021 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2021 USD ($) performance_obligation	Dec. 31, 2021 EUR (€) performance_obligation	Dec. 31, 2020 USD ($)	Jan. 01, 2019 USD ($)	May 02, 2017 lease_agreement	May 02, 2017 performance_obligation	May 02, 2017 collaboration_product
Disaggregation of Revenue [Line Items]
Deferred revenues, current portion																														$ 25,116		$ 12,627
Deferred revenue, net of current portion																														38,403		35,900
Revenue recognized from contract with customer																														11,000
Number of technology licenses (in licenses) \| lease_agreement													5
Revenues																														31,418		29,323
Number of separate performance obligations (in performance obligations) \| performance_obligation																				1
Amortization of capitalized contract costs																																100
Additions to contract with customer, liability																														31,600
Genentech
Disaggregation of Revenue [Line Items]
Fee on additional program		$ 10,000
Termination notice period within material breach	90 days
Before first commercial sale	90 days
After first commercial sale	180 days
Number of research programs			4		2
Remaining performance obligation																														16,600
Revenues																														1,950		0
Genentech \| License fees
Disaggregation of Revenue [Line Items]
Deferred revenue	$ 20,000	$ 20,000	$ 20,000	$ 20,000	$ 20,000
Deferred revenues, current portion																														8,100
Deferred revenue, net of current portion																														8,500
Genentech \| Research and development services
Disaggregation of Revenue [Line Items]
Research collaboration agreement term	3 years
Boston Pharmaceuticals \| License fees
Disaggregation of Revenue [Line Items]
Remaining performance obligation						$ 6,000
Contract with customer asset, after allowance for credit loss						4,000
Seagen
Disaggregation of Revenue [Line Items]
Number of performance obligations \| performance_obligation										3
Remaining performance obligation																														21,500
Deferred revenues, current portion																														10,300
Deferred revenue, net of current portion																														8,200
Amended collaboration agreement, resale of stock, period									60 days
Revenues																														768		9,702
Seagen \| Private Placement
Disaggregation of Revenue [Line Items]
Deferred revenue									$ 3,300
Shares of common stock issued (shares) \| shares									3,706,174
Net proceeds from private placement									$ 13,000
Issue price per share (USD per share) \| $ / shares									$ 3.51
Fair value of stock (in dollars per share) \| $ / shares									$ 2.61
AstraZeneca
Disaggregation of Revenue [Line Items]
Deferred revenue																														700
Research collaboration agreement term											5 years
Remaining performance obligation																														18,700
Deferred revenues, current portion																														900
Deferred revenue, net of current portion																														17,000
Revenues																									$ 13,000					18,919		8,308
AstraZeneca \| Private Placement
Disaggregation of Revenue [Line Items]
Shares of common stock issued (shares) \| shares							3,584,230	3,584,230
Net proceeds from private placement							$ 10,000
Issue price per share (USD per share) \| $ / shares							$ 2.79
Fair value of stock (in dollars per share) \| $ / shares							$ 2.60
Servier
Disaggregation of Revenue [Line Items]
Number of performance obligations \| performance_obligation																				10
Remaining performance obligation																														10,400
Deferred revenues, current portion																														5,800
Deferred revenue, net of current portion																														4,600
Revenue recognized from contract with customer																													$ 7,100
Number of novel proteins (in proteins) \| bispecific_therapeutic_program																							1
Number of research programs (in research programs)																					3		3				5
Revenues																														4,070		11,313
Capitalized contract cost, net																														$ 100
Research term extension period																										12 months	12 months
Number of separate performance obligations (in performance obligations) \| performance_obligation																				2
Number of combined performance obligations (in obligations) \| performance_obligation																				2
Number of preclinical stage programs (in programs) \| program																											2
Period to complete remaining obligations on programs																											60 days
Servier \| Research and development services
Disaggregation of Revenue [Line Items]
Research collaboration agreement term																		3 years
Number of development milestones \| performance_obligation																														4	4
License and collaboration agreement \| Genentech
Disaggregation of Revenue [Line Items]
Number of performance obligations \| performance_obligation				5
License and collaboration agreement \| Seagen
Disaggregation of Revenue [Line Items]
Number of research programs \| research_program										3
Number of performance obligations \| performance_obligation										6
Period after effective date agreements may be terminated										12 months
Contract termination advance notice period										90 days
Agreement termination advance notice period if marketing approval obtained										180 days
Agreement termination notice period upon material breach by the Company										90 days
Contract termination due to material breach, additional notice period if the breach is not susceptible										90 days
Number of licenses \| license										3
Number of Swap options \| swap_option										2
License and collaboration agreement \| AstraZeneca
Disaggregation of Revenue [Line Items]
Number of performance obligations \| performance_obligation														16
Period after effective date agreements may be terminated											12 months
Contract termination advance notice period											90 days
Agreement termination advance notice period if marketing approval obtained											180 days
Agreement termination notice period upon material breach by the Company											180 days
Contract termination due to material breach, additional notice period if the breach is not susceptible											180 days
Number of novel proteins (in proteins) \| protein																	4
Agreement termination notice period upon breach of payment obligations by the Company											30 days
Period of license performance obligation											12 months
Revenues																														$ 13,000
License and collaboration agreement \| Servier
Disaggregation of Revenue [Line Items]
Number of performance obligations \| performance_obligation																				4
Number of licenses \| license																						5
Number of collaboration products (in collaboration products) \| collaboration_product																		2	2	2	2	2	2	2
Number of research programs (in research programs) \| bispecific_therapeutic_program																							5
Collaborative arrangement \| Servier
Disaggregation of Revenue [Line Items]
Period after effective date agreements may be terminated																		12 months
Revenue recognized from contract with customer																														4,300	€ 3.8
Contract termination advance notice period																		180 days
Number of collaboration products (in collaboration products) \| product																		4	4	4	4	4	4	4
Co-development collaboration product \| Servier
Disaggregation of Revenue [Line Items]
Number of collaboration products (in collaboration products) \| collaboration_product																											1
Servier developed collaboration product \| Servier
Disaggregation of Revenue [Line Items]
Number of collaboration products (in collaboration products) \| collaboration_product																											1
Other arrangement \| Seagen
Disaggregation of Revenue [Line Items]
Number of research programs \| research_program										2
Platform technology license \| Genentech
Disaggregation of Revenue [Line Items]
Number of performance obligations \| performance_obligation				2
Number of target programs \| program					2
Platform technology license \| Seagen
Disaggregation of Revenue [Line Items]
Number of performance obligations \| performance_obligation										3
Number of target programs \| program										3
Antibody target swap \| Genentech
Disaggregation of Revenue [Line Items]
Number of performance obligations \| performance_obligation				2
Antibody target swap \| Seagen
Disaggregation of Revenue [Line Items]
Number of performance obligations \| performance_obligation										2
Governance committee participation \| Genentech
Disaggregation of Revenue [Line Items]
Number of performance obligations \| performance_obligation				1
Governance committee participation \| Seagen
Disaggregation of Revenue [Line Items]
Number of performance obligations \| performance_obligation										1
Upfront payment \| Boston Pharmaceuticals \| License fees
Disaggregation of Revenue [Line Items]
Remaining performance obligation						10,000
Upfront payment \| Seagen
Disaggregation of Revenue [Line Items]
Research and development services										$ 4,900
Upfront payment \| Seagen \| License fees
Disaggregation of Revenue [Line Items]
Revenue										$ 30,000
Upfront payment \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration												$ 45,000
Upfront payment \| Servier \| License fees
Disaggregation of Revenue [Line Items]
Revenue																			$ 32,000					€ 30.0
Additional other research services \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration												4,700
Exclusive Product License Agreement \| Boston Pharmaceuticals \| License fees
Disaggregation of Revenue [Line Items]
Deferred revenue						10,000
Remaining performance obligation																														5,700
Contribution on manufacturing (up to)						$ 4,000
Period after effective date agreements may be terminated						9 months
Contract termination advance notice period						60 days
Agreement termination advance notice period if marketing approval obtained						120 days
Agreement termination notice period upon material breach by the Company						180 days
Agreement termination notice period due to non-payment of undisputed amounts						60 days
Contract termination due to material breach, additional notice period if the breach is not susceptible						180 days
Collaborative arrangement, agreement obligation cost						$ 4,000
Estimated development and manufacturing services \| Upfront payment \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration												14,200
Milestone payments \| Upfront payment \| Seagen
Disaggregation of Revenue [Line Items]
Revenue recognized from contract with customer																												$ 4,200
Allocable arrangement consideration																													$ 5,000
Milestone payments \| Upfront payment \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration												12,500
Estimated phase 2a services \| Upfront payment \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration												4,700
Agreement extension options \| Servier \| Research and development services
Disaggregation of Revenue [Line Items]
Research collaboration agreement term																		1 year
Number of agreement extension options (extension options) \| performance_obligation																				2
Minimum \| License and collaboration agreement \| AstraZeneca
Disaggregation of Revenue [Line Items]
Number of collaboration products (in collaboration products) \| collaboration_product																																				2
Minimum \| Collaborative arrangement \| Servier
Disaggregation of Revenue [Line Items]
Agreement termination notice period upon material breach by the Company																		90 days
Maximum \| License and collaboration agreement \| AstraZeneca
Disaggregation of Revenue [Line Items]
Number of collaboration products (in collaboration products)																		4	4	4	4	4	4	4										4	4	4
Number of research programs (in research programs) \| research_program															2
Number of research licenses (in licenses)													4			4						4
Maximum \| Collaborative arrangement \| Servier
Disaggregation of Revenue [Line Items]
Agreement termination notice period upon material breach by the Company																		120 days
Accounting Standards Update 2014-09 \| AstraZeneca
Disaggregation of Revenue [Line Items]
Capitalized contract cost, net											$ 1,600	$ 1,600	$ 1,600	$ 1,600	$ 1,600	$ 1,600	$ 1,600													$ 600		$ 600
Capitalized contract cost in accordance with ASC 340																																	$ 1,100
Accounting Standards Update 2014-09 \| Servier
Disaggregation of Revenue [Line Items]
Capitalized contract cost, net																																	$ 500